ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Temporal Gating Through HSP70 ATPase Cycle Manipulation
Compounds that extend HSP70's ATPase cycle specifically when bound to tau substrates, trapping tau in non-productive chaperone complexes and leading to tau sequestration and degradation through quality control pathways.
drug discovery
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Compounds that extend HSP70's ATPase cycle specifically when bound to tau substrates, trapping tau in non-productive chaperone complexes and leading to tau sequestration and degradation through quality control pathways.
🧬 Mechanism
🔗 Mechanism from KG for HSPA1A
Auto-built from this analysis's top knowledge-graph edges.
graph TD
HSPA1A["HSPA1A"] -->|protein interactio| STUB1["STUB1"]
MAPT["MAPT"] -->|regulates| HSPA1A_1["HSPA1A"]
Bifunctional_PROTACs["Bifunctional PROTACs"] -->|targets| HSPA1A_2["HSPA1A"]
HSPA1A_3["HSPA1A"] -->|regulates| tau_protein["tau protein"]
HSPA1A_4["HSPA1A"] -->|regulates| proteasomal_degradation_p["proteasomal degradation pathway"]
style HSPA1A fill:#ce93d8,stroke:#333,color:#000
style STUB1 fill:#ce93d8,stroke:#333,color:#000
style MAPT fill:#ce93d8,stroke:#333,color:#000
style HSPA1A_1 fill:#ce93d8,stroke:#333,color:#000
style Bifunctional_PROTACs fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_2 fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_3 fill:#4fc3f7,stroke:#333,color:#000
style tau_protein fill:#4fc3f7,stroke:#333,color:#000
style HSPA1A_4 fill:#4fc3f7,stroke:#333,color:#000
style proteasomal_degradation_p fill:#81c784,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports1 contradicts
Supports
Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
Supports
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system.
Supports
Mechanism of Tau protein incorporation into exosomes via cooperative recognition of KFERQ-like motifs by LAMP2A and HSP70.
Contradicts
From sleep to cancer to neurodegenerative disease: the crucial role of Hsp70 in maintaining cellular homeostasis and potential therapeutic implications.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HSPA1A
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HSPA1A.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0511
Events (7d)
0
Price History
▲5.2%💾 Resource Usage
LLM Tokens
18,738
$0.1124
Total Cost
$0.1124
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF HSPA1A ATPase inhibition (15 μM PES) is applied to iPSC-derived cortical neurons from a PSP patient cohort for 48 hours, THEN total tau protein will be reduced by >50% relative to vehicle controls, | >50% reduction in total tau (normalized to βIII-tubulin loading control) in treatment vs. control; reversal of effect with bortezomib co-treatment. | — no observation — | pending | 0.58 |
| IF HSPA1A ATPase activity is selectively inhibited (e.g., 2-phenylethynesulfonamide at 20 μM) in human neuroglioma cells overexpressing 2N4R tau for 24 hours, THEN tau-HSPA1A complex abundance will in | Increased tau-HSPA1A complex formation (+>100%) and reduced soluble tau concentration (-40%), both quantified by co-immunoprecipitation and quantitative western | — no observation — | pending | 0.62 |
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF HSPA1A ATPase activity is selectively inhibited (e.g., 2-phenylethynesulfonamide at 20 μM) in human neuroglioma cells overexpressing 2N4R tau for 24 hours, THEN tau-HSPA1A complex abundance will increase >2-fold and free cytosolic tau will decrease >40% compared to DMSO-treated controls, because
Predicted outcome: Increased tau-HSPA1A complex formation (+>100%) and reduced soluble tau concentration (-40%), both quantified by co-immunoprecipitation and quantitati
Falsification: No significant change in tau-HSPA1A complex abundance (<20% increase) or tau levels unchanged/increased after ATPase inhibition would disprove the mechanism.
pendingconf 58%
IF HSPA1A ATPase inhibition (15 μM PES) is applied to iPSC-derived cortical neurons from a PSP patient cohort for 48 hours, THEN total tau protein will be reduced by >50% relative to vehicle controls, and this effect will be completely abolished by co-treatment with proteasome inhibitor bortezomib (
Predicted outcome: >50% reduction in total tau (normalized to βIII-tubulin loading control) in treatment vs. control; reversal of effect with bortezomib co-treatment.
Falsification: Bortezomib fails to block tau reduction, or tau levels do not decrease >30% despite ATPase inhibition, would indicate HSP70-independent mechanism.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.